e-mail: voso@med.uniroma2.it |
Prof. Maria Teresa VosoCURRICULUM VITAE
1990 Laurea in Medicina e Chirurgia, Universita’ Cattolica del Sacro Cuore, Roma 1992-1994 Stage di Ricerca presso il Laboratorio del Prof. Daniel G. Tenen, Harvard Medical School, Boston, USA. 1994 Specializzazione in Ematologia, Universita’ Cattolica del Sacro Cuore, Roma 1995 Medico borsista presso l’Istituto di Semeiotica Medica, Universita' Cattolica S. Cuore, Roma 1996-1999 Ricercatore presso l' Unita' Cooperativa Ematologia-Oncologia fra Universita` di Heidelberg e l’ Istituto tedesco per la Ricerca sul Cancro (DKFZ), Heidelberg, Germania 1999-2002 Dirigente Medico presso l’Istituto di Ematologia dell’ Universita’ Cattolica S. Cuore, Roma 2002-2014 Professore Aggregato, Istituto di Ematologia, Universita’ Cattolica Sacro Cuore, Roma, e dirigente medico presso il reparto di Ematologia, Policlinico Gemelli, Roma 2014- Professore Associato di Malattie del Sangue, Universita’ di Roma Tor Vergata Metrics: 162 peer-reviewed full-text publications, H-index (WOS): 32 Pubblicazioni rilevanti
Voso MT, et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Ann Oncol 2017; 28:1547-1553 Fabiani E, …& Voso MT Clonal evolution in therapy-related neoplasms. Oncotarget 2017; 8: 12031-12040 Cicconi L, .., Voso MT, Mandelli F, Lo-Coco F. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia 2016; 30: 1987-1992 Della Porta MG, … Voso MT, …Cazzola M. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol 2016. pii: JCO673616 Fianchi L, …, & Voso MT. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol 2015; 90: 80-85 Voso MT, Lo-Coco F, Fianchi L. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Oncol 2015; 27: 532-539 Voso MT, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol 2013; 31: 2671-2677 Voso MT, et al Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. Leukemia 2013; 27: 982-985 Voso MT, et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009;15: 5002-7 |